Latest News

Latest News

Clinical Trial Results 13 November 2026

Clinical Trial Results 13 November 2026

Clinical trial results 13 November 2026: obesity and cardiovascular risk, sleep apnoea, hepatitis delta, hidradenitis suppurativa, triglycerides and peanut allergy. Boehringer Ingelheim’s survodutide met its cardiovascular non-inferiority endpoint in obesity. Eli...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

Weekly News Roundup | 2 November 2026

Weekly News Roundup | 2 November 2026

Life science news 2 November 2026: four approvals, three deals and a UK Budget investment package. Ferring has agreed to acquire Gameto in a deal worth up to $1.3825bn. The FDA granted accelerated approval to Voceryq for recurrent respiratory papillomatosis. The MHRA...

read more
What Are You Signing When the AI Wrote the Note?

What Are You Signing When the AI Wrote the Note?

Anyone who has finished an emergency shift knows the chart stack. The department is still loud, the next team has the board, and a column of unsigned notes waits on the workstation. You read each one, fix what's wrong, and sign. That signature has always meant...

read more
Clinical Trial Results 30 October 2026

Clinical Trial Results 30 October 2026

Clinical trial results 30 October 2026: head and neck cancer, small cell lung cancer, type 2 diabetes and breast cancer. Genmab’s petosemtamab plus pembrolizumab met both co-primary endpoints in first-line PD-L1-positive head and neck cancer. Amgen’s tarlatamab plus...

read more
Retatrutide vs Ozempic: How Do They Compare in Diabetes?

Retatrutide vs Ozempic: How Do They Compare in Diabetes?

Retatrutide vs Ozempic now has a head-to-head answer in type 2 diabetes. In an 80-week phase 3 trial, retatrutide lowered A1C by 2.2 percentage points, against 1.8 for Ozempic 2 mg. Body weight fell by 19.5 to 20.9 per cent on retatrutide and 9.4 per cent on Ozempic....

read more
Interoperability Begins Where Data Exchange Ends

Interoperability Begins Where Data Exchange Ends

Standards and APIs can move information. True healthcare interoperability requires the governance, trust and workflow design that make the information usable. Healthcare has spent years treating interoperability as a problem of moving data. National exchange has...

read more
Weekly News Roundup | 2 November 2026

Weekly News Roundup | 2 November 2026

Life science news 2 November 2026: four approvals, three deals and a UK Budget investment package. Ferring has agreed to acquire Gameto in a deal worth up to $1.3825bn. The FDA granted accelerated approval to Voceryq for recurrent respiratory papillomatosis. The MHRA...

read more
What Are You Signing When the AI Wrote the Note?

What Are You Signing When the AI Wrote the Note?

Anyone who has finished an emergency shift knows the chart stack. The department is still loud, the next team has the board, and a column of unsigned notes waits on the workstation. You read each one, fix what's wrong, and sign. That signature has always meant...

read more
Clinical Trial Results 30 October 2026

Clinical Trial Results 30 October 2026

Clinical trial results 30 October 2026: head and neck cancer, small cell lung cancer, type 2 diabetes and breast cancer. Genmab’s petosemtamab plus pembrolizumab met both co-primary endpoints in first-line PD-L1-positive head and neck cancer. Amgen’s tarlatamab plus...

read more
Retatrutide vs Ozempic: How Do They Compare in Diabetes?

Retatrutide vs Ozempic: How Do They Compare in Diabetes?

Retatrutide vs Ozempic now has a head-to-head answer in type 2 diabetes. In an 80-week phase 3 trial, retatrutide lowered A1C by 2.2 percentage points, against 1.8 for Ozempic 2 mg. Body weight fell by 19.5 to 20.9 per cent on retatrutide and 9.4 per cent on Ozempic....

read more
Interoperability Begins Where Data Exchange Ends

Interoperability Begins Where Data Exchange Ends

Standards and APIs can move information. True healthcare interoperability requires the governance, trust and workflow design that make the information usable. Healthcare has spent years treating interoperability as a problem of moving data. National exchange has...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Eppendorf and BioLabs Expand Collaboration to Munich

Eppendorf and BioLabs Expand Collaboration to Munich

The collaboration will provide laboratory equipment, technical support and engagement opportunities for BioLabs resident companies. It builds on existing partnerships at BioLabs sites across the US, Germany and France. HAMBURG and MUNICH, Germany, 21 October 2026...

read more
ZW209 Licensing Deal: What Does Roche Get From Zymeworks?

ZW209 Licensing Deal: What Does Roche Get From Zymeworks?

Under the ZW209 licensing deal with Zymeworks, Roche will receive exclusive global rights to develop and commercialise ZW209. In return, Zymeworks is due $55 million upfront and $40 million when a Phase 1b trial begins. It is also eligible for up to $718 million in...

read more
OOS Investigation: A Solubility-Related HPLC Assay Failure

OOS Investigation: A Solubility-Related HPLC Assay Failure

A low out-of-specification (OOS) assay result does not always originate in the analytical laboratory. In pharmaceutical manufacturing, an OOS investigation must consider laboratory testing, raw material properties, manufacturing instructions and process execution...

read more
Connecting ADME and Mouse Models in Preclinical Oncology

Connecting ADME and Mouse Models in Preclinical Oncology

In preclinical oncology, a tumor study can show little benefit even when a candidate has strong activity in cultured cells. Before abandoning the compound, researchers need to establish what the result means. Did enough drug reach the tumor? Was the proposed target...

read more

Further News

AI in Drug Discovery Is Great. Don’t Forget About AI in Drug Development

Artificial intelligence and the buzz around it feel like they're moving at warp speed. As this acceleration continues, especially in the life sciences, we need to pause and understand the vast differences between two uses of artificial intelligence that couldn’t be...

MariTide Approval: When Could Amgen’s Obesity Drug Reach Patients?

MariTide approval cannot be decided until Amgen files, and a search on 5 November 2026 found no filing announcement. BioSpace reported on 4 November 2026 that the first Phase 3 data are expected in 2027. The same report gave no regulatory filing timeline. Amgen’s...

In Vivo CAR-T Is Shifting the Engineering Challenge Into Delivery

CAR T-cell therapy is revolutionizing cancer treatment and being applied to a variety of other indications, but the approach relies on engineering a patient’s immune cells to recognize and attack cancer. Producing those cells can involve a complex, resource- and...

AbbVie Nxera Deal: What Does AbbVie Get for $100 Million Upfront?

The AbbVie Nxera deal gives AbbVie exclusive worldwide rights to develop and commercialise NXE0033744 in inflammatory bowel disease (IBD). The price is $100 million upfront, plus up to $1.37 billion in milestones and tiered royalties. Nxera Pharma announced the...

Hygiene Poverty and the Overlooked Toileting Needs of Women

If you had to choose between food and toilet paper, what would you choose? A UK report from In Kind Direct and The Hygiene Bank found that 47% of people experiencing hygiene poverty had gone without toilet roll, making it the most common product people went without....

Pharma Q3 2026 Earnings: GLP-1s, the Keytruda Cliff and Vaccines

Eli Lilly began 2026 expecting revenue of $80bn to $83bn. After its third quarter, it now expects $91bn to $92bn. Lilly’s sales reached $24.4bn in the three months to September, up 39%. Most of its large peers grew in single digits. Read together, pharma Q3 2026...

Preservative-Free Is Not Risk-Free: The Microbiology Behind Safe Cosmetics

I have noticed that many shoppers want cosmetics without preservatives, so brands have launched preservative-free cosmetics and other “free-from” lines. The science of microbiology however stays the same. Any product that holds water and nutrients can feed microbes....

COMP360 Approval: When Could Compass’s Psilocybin Be Cleared?

COMP360 approval timing: Compass expects to finish its psilocybin NDA within weeks. See what the FDA voucher target means for a decision.

    What Happens After a Digital Mental Health Screening Result

    A self-assessment can identify symptoms, but the value of mental health screening depends on what people understand, choose and can access after seeing the result. A person completes an online mental health questionnaire and receives a score suggesting that...

    Rethinking Biologics Plants to Earn Attractive Returns

    The rapid growth of biologics and other advanced therapeutic modalities is transforming pharmaceutical R&D and manufacturing. From monoclonal antibodies and oligonucleotides to cell and gene therapies, these products introduce a level of process complexity,...

    BioMarin Fabry Deal: What Does It Get for $70 Million Upfront?

    BioMarin has licensed HM15421/GC1134A, an early-stage subcutaneous Fabry enzyme therapy, from GC Biopharma and Hanmi Pharm for $70 million upfront.

      The Fifty-Year Chase: Where Noninvasive Glucose Monitoring Stands in 2026

      For nearly half a century, one problem has raised more capital, had more publications, and experienced more failed product launches than almost any other in medical devices: noninvasive glucose monitoring, or measuring blood glucose without breaking the skin. More...

      Want to Be Part of the Next Chapter in Life Sciences Media?

       

      LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

       

       

      Don’t wait for the media to pick up your story. Be the media.

      See More Articles

      Want to Be Part of the Next Chapter in Life Sciences Media?

       

      LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

       

       

      Don’t wait for the media to pick up your story. Be the media.